All the work that goes into creating an effective therapeutic product means nothing if that treatment can't reach the patients who need it. But whether for financial, geographic, or logistical reasons, access to treatment remains an ongoing challenge for many patients around the world. That's why at Sanofi Genzyme, our commitment to patients – and our efforts to ensure their access to our therapies – extends far beyond the lab and manufacturing plant.
We understand that many patients and their families may have particular interest in accessing Sanofi Genzyme’s therapies prior to their approval. While safety is our priority, we may provide eligible patients, without any available treatment options, access to an unapproved investigational treatment through our compassionate use program.
For more information, please visit Sanofi’s Compassionate Use Policy.
Sanofi Genzyme works with local governments around the world to secure timely approval of our products. While approvals are pending, we've helped patients with urgent medical needs obtain access to our therapies through compassionate use or expanded access programs. We work with national health services and private insurers to establish coverage for our products. And where coverage is not available, we work to facilitate free treatment access, help patients find alternative funding, and help countries establish sustainable health care systems. We also provide a range of educational and support services to raise disease awareness and advocate on behalf of patients' needs.